December 14, 2018
ARLINGTON, Va. — “While HDA cannot speak to the specifics of the litigation, it defies common sense to single out distributors for the opioid crisis. As logistics experts, distributors do not manufacture, promote or prescribe opioids, influence clinical decision-making or in any way drive demand for the product. Distributors deliver medicines prescribed by a licensed physician and ordered by a licensed pharmacy.
“Distributors have a limited, yet critical role in the pharmaceutical supply chain. In addition to ensuring that all medicines are delivered safely and efficiently, distributors work with state, local and federal law enforcement to stem diversion before it occurs. Distributors have submitted thousands of suspicious order reports to the DEA.
“We believe these lawsuits are misplaced. Nonetheless, we are committed to continuing to work with all stakeholders across the healthcare community as well as policymakers to advance practical solutions that address the crisis and prevent misuse and abuse.”
Healthcare distributors are the backbone of the U.S. healthcare ecosystem, serving as the vital link connecting 1,400 pharmaceutical manufacturers to more than 180,000 individual pharmacies, hospitals and healthcare facilities.
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.